Delayed failure of rectovaginal fistula embolization with Amplatzer vascular plug 2

We read with great interest the paper published by Guneyli et al. (1) in Diagnostic and Interventional Radiology along with the other impressive papers regarding the use of Amplatzer® Vascular Plugs (AVPs, AGA Medical Corp., Golden Valley, Minnesota, USA) (1–3). We would like to share our experience about using the AVP for treating a rectovaginal fistula (RVF). Although initially successful, this treatment unfortunately failed in the long-term follow-up.

A 47-year-old female patient was referred to our department for interventional radiologic treatment of RVF, which occurred following a low anterior resection for T2N0M0 rectal cancer, performed 10 months ago in another center. On postoperative day 12 the patient suffered vaginal fecal discharge. Initial emergent loop diversion colostomy and primary surgical repair of the fistula six months later, were both unsuccessful. Double-contrast barium enema (Prontobario Colon, Bracco, Milan, Italy) revealed passage of contrast and air from rectum to vagina consistent with RVF, and embolization of the fistula was planned (Fig. 1a).

Under the guidance of a 5 F vertebral catheter (Cordis, Johnson & Johnson, Miami, Florida, USA) and an angled hydrophilic 0.035-inch radiofocus glidewire (Terumo, Somerset, New Jersey, USA) the fistula was catheterized, and the wire accessed into the vaginal lumina. The glidewire was exchanged for a stiff Amplatz guidewire (Cook Medical, Bloomington, Indiana, USA). An 8 F long sheath and a dilator (Shuttle, Cook Medical) were inserted over the exchange wire into the fistula and advanced to the measured area. The dilator and the wire were removed, and angiography was performed through the guiding catheter to confirm satisfactory location of the guiding catheter. An AVP 2 was introduced through the 8 F sheath. While the medial part of the plug was in the fistula, the distal and proximal parts were in the vaginal and rectal walls, respectively (Fig. 1). The plug was deployed following confirmation of the device position. Postembolization angiography revealed occlusion of the fistula. The patient was discharged the next day. The control double-contrast barium enema examination at the first month revealed complete healing and the patient was free of symptoms (Fig. 2).

However, the second control imaging performed at the third month, after relapsed complaints of the patient, revealed loss of the plug and reappearance of the fistula. In addition, there was a new blind-ended fistula towards the presacral space (Fig. 3). Although we could not demonstrate direct passage of contrast into vagina, there was a late slight fluid discharge consistent with contrast material from the vagina.
First-line treatment options for this patient include palliative colostomy and surgical repair. An alternative method could be the use of an occlusion device designed for nonsurgical treatment of patients with acquired RVF, as reported by Lee et al. (4). Although this device is reported to have a high success rate, there are certain limitations: each device should be constructed according to the diameter and length of the fistula tract and deployed through a 24 F chest tube.

In this letter we present a case of initially successful nonsurgical technique for RVF treatment. To the best of our knowledge this is the first case in the literature reporting the use of an AVP in RVF. The late-onset failure and loss of AVP might be related to physiological rises in rectal pressure during the passage of stool and regional movements.

Since the introduction of AVPs for use in the cardiovascular system, various applications have been reported in different diseases and organ systems. Their applicability and effectiveness have been proved in numerous vascular diseases along with reports confirming successful use in esophagobronchial, gastrocolonic, and ureterovesical fistulas (1–3).

In conclusion, RVFs are rare complications of various diseases or surgical procedures, and they should be treated immediately for distressing symptoms. The long-term failure of AVP must be kept in mind, when considering treatment options.

Conflict of interest disclosure
The authors declared no conflicts of interest.

References